Jefferies Financial Group Inc. lowered its holdings in Verastem, Inc. (NASDAQ:VSTM – Free Report) by 16.6% during the third quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm owned 414,241 shares of the biopharmaceutical company’s stock after selling 82,288 shares during the quarter. Jefferies Financial Group Inc.’s holdings in Verastem were worth $3,335,000 as of its most recent SEC filing.
A number of other hedge funds and other institutional investors have also recently made changes to their positions in the business. Commonwealth Equity Services LLC acquired a new position in Verastem during the third quarter valued at $122,000. Aries Wealth Management boosted its holdings in Verastem by 6.5% in the third quarter. Aries Wealth Management now owns 32,833 shares of the biopharmaceutical company’s stock valued at $264,000 after purchasing an additional 2,000 shares during the last quarter. Simplicity Wealth LLC acquired a new stake in Verastem during the 3rd quarter worth about $89,000. Opaleye Management Inc. acquired a new stake in Verastem during the 2nd quarter worth about $6,876,000. Finally, Bank of New York Mellon Corp acquired a new stake in Verastem during the 2nd quarter worth about $706,000. Institutional investors and hedge funds own 88.37% of the company’s stock.
Insider Transactions at Verastem
In other news, CEO Dan Paterson sold 44,121 shares of Verastem stock in a transaction dated Thursday, October 1st. The shares were sold at an average price of $8.00, for a total value of $352,968.00. Following the sale, the chief executive officer owned 652,712 shares in the company, valued at $5,221,696. This trade represents a 6.33% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold 48,041 shares of company stock worth $386,390 over the last quarter. Company insiders own 1.94% of the company’s stock.
Verastem Trading Down 7.2%
Shares of NASDAQ:VSTM opened at $8.44 on Friday. Verastem, Inc. has a 1 year low of $3.43 and a 1 year high of $10.82. The firm has a market capitalization of $764.33 million, a price-to-earnings ratio of -4.12 and a beta of 0.45. The company has a debt-to-equity ratio of 11.19, a current ratio of 1.93 and a quick ratio of 2.22. The business’s 50 day moving average price is $8.48 and its 200-day moving average price is $6.29.
Verastem (NASDAQ:VSTM – Get Free Report) last issued its quarterly earnings results on Thursday, November 5th. The biopharmaceutical company reported ($0.74) EPS for the quarter, missing the consensus estimate of ($0.47) by ($0.27). The company had revenue of $24.01 million during the quarter, compared to analysts’ expectations of $26.57 million. Verastem had a negative return on equity of 359.49% and a negative net margin of 178.38%. On average, equities research analysts forecast that Verastem, Inc. will post -1.72 earnings per share for the current fiscal year.
Wall Street Analysts Forecast Growth
VSTM has been the subject of a number of recent research reports. Royal Bank Of Canada reduced their price objective on Verastem from $19.00 to $18.00 and set an “outperform” rating for the company in a research note on Friday, November 6th. Benchmark restated a “buy” rating on shares of Verastem in a research note on Friday, October 16th. Wall Street Zen lowered Verastem from a “hold” rating to a “sell” rating in a report on Saturday, November 7th. Mizuho lifted their price target on Verastem from $13.00 to $14.00 and gave the company an “outperform” rating in a research report on Friday, October 16th. Finally, HC Wainwright lifted their price target on Verastem from $18.00 to $20.00 and gave the company a “buy” rating in a research report on Friday, November 6th. Eleven equities research analysts have rated the stock with a Buy rating, one has given a Hold rating and one has assigned a Sell rating to the company. According to MarketBeat.com, the company has a consensus rating of “Moderate Buy” and an average target price of $16.83.
Get Our Latest Research Report on VSTM
Verastem Company Profile
Verastem, Inc. is a biopharmaceutical company focused on developing and commercializing medicines for cancer. Its research has centered on signaling pathways involved in tumor growth, including the RAS/MAPK pathway. The company’s product, AVMAPKI FAKZYNJA CO-PACK, combines avutometinib and defactinib. The U.S. Food and Drug Administration approved the combination for certain adults with KRAS-mutated recurrent low-grade serous ovarian cancer who have received prior systemic therapy. Verastem is based in Needham, Massachusetts, and also develops investigational cancer therapies, including potential uses of avutometinib in combination with other medicines.
Read More
- Five stocks we like better than Verastem
- Checkmate for AI Chips? NVIDIA’s Crisis Opens the Board
- Can NVIDIA Maintain Its Momentum Without Huang?
- Six Flags Lost $366 Million in Q3—Its Insiders Just Went Shopping
- What Went Wrong With Amprius Technologies’ Q3? Less Than You’d Think
Want to see what other hedge funds are holding VSTM? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Verastem, Inc. (NASDAQ:VSTM – Free Report).
Receive News & Ratings for Verastem Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Verastem and related companies with MarketBeat.com's FREE daily email newsletter.
